Demethoxycurcumin was prior to temozolomide on inhibiting proliferation and induced apoptosis of glioblastoma stem cells.

摘要: Temozolomide (TMZ) is widely used for treating glioblastoma (GBM), which can effectively inhibit the GBM growth some months; however, it still could not prevent invariable recurrence of GBM. The existence glioma stem cells (GSCs) was considered to be a key factor. But TMZ has poor effects on GSCs. Recently, demethoxycurcumin (DMC) been shown display anti-tumor activities in malignant gliomas. However, its and potential mechanisms GSCs were unclear. Our study showed that DMC prior resulting significant increase GSC apoptosis marked inhibition cell vitro. And combined treatment more anti-GSC effects. Further research into underlying mechanism demonstrated this novel combinatorial regimen leads changes multiple signaling pathways including reactive oxygen species (ROS) production caspase-3 mitochondria-related activation as well inactivation JAK/STAT3 pathway. Taken together, our data demonstrate are better than TMZ, much stronger